DEFINERx050: A Multicentre, Randomized, Open-Label Study of Atezolizumab [Anti-PD-L1 Antibody] Plus Bevacizumab [Anti-VEGF Antibody] as Neo-Adjuvant therapy Versus Active Surveillance in Hepatocellular Carcinoma Patients with High Onco-Fetal Characteristics Before Surgical Resection (ACTRN12624001345572)

Evaluate the efficacy and safety of neoadjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance prior to surgical resection in early-stage HCC patients who are at high risk for disease recurrence.

Trial phase

Phase 2

Trial participation type

This trial is for clinical research of something other than a drug or device.

Principal investigator

Prof Stuart Roberts

Key inclusion data

Inclusion: participants with early-stage HCC who have been recommended by the local MDT to undergo curative surgical resection. . Exclusion criteria: Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC Evidence of residual, recurrent, or metastatic disease